Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

No phase data available

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT02471625Unknown

Traumatic Brain Injury Feasibility Study (EPIC-011)

Role: lead

NCT02287766Completed

Metabolic Syndrome Feasibility Study

Role: lead

NCT01740739Suspended

Evaluation Using ClearView in Determining Association to the Cardiac Risk Factors

Role: lead

NCT01476982Unknown

Evaluation of Patients in Chest Pain in the Emergency Room

Role: lead

NCT01573559Completed

ClearView Predicate Comparison Testing

Role: lead

NCT01476995Completed

Prognostic Indicators as Provided by the EPIC ClearView

Role: lead

All 6 trials loaded